3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
26
Gastrointestinal
5
Thoracic
4
Gynecologic
4
Head & Neck
2
Genitourinary
2
Other solid neoplasm
1
Conditions
Advanced Solid Tumors
10
Solid Tumors
8
Solid Tumor
8
Unspecified Adult Solid Tumor, Protocol Specific
7
Mesothelioma
6
Mesothelioma, Malignant
3
Advanced Solid Tumor
3
Advanced/Metastatic Solid Tumors
2
Advanced Solid Tumour
2
Uterine Neoplasms
1
Unspecified Childhood Solid Tumor, Protocol Specific
1
Unspecified Adult Solid Tumor
1
Triple Negative Breast Neoplasms
1
Solitary Fibrous Tumor, Pleural
1
Solid Tumor, Adult
1
Select Advanced Solid Tumors
1
Refractory Solid Tumors in Children
1
Ovarian Neoplasms
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Malignant Solid Tumour
1
MSI-H Advanced Colorectal Cancer
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Cervical Adenocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Neuroendocrine
1
Carcinoma, Merkel Cell
1
Breast Neoplasms
1
Advanced HCC
1
Interventions
pembrolizumab
6
Nivolumab
3
budigalimab
2
Paclitaxel
2
Ipilimumab
2
Docetaxel
2
venetoclax
1
tislelizumab
1
talazoparib
1
spartalizumab
1
rovalpituzumab tesirine
1
regorafenib
1
obinutuzumab
1
naptumomab estafenatox
1
fludarabine
1
epacadostat
1
durvalumab
1
cabozantinib
1
Platinum
1
Levoleucovorin
1
Leucovorin
1
Interleukin-2
1
IPI-549
1
Gemcitabine
1
Fluorodeoxyglucose F18
1
Everolimus
1
Cyclophosphamide
1
Clinical Trials, Phase II as Topic
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Bevacizumab
×
Other solid neoplasm
×
Clear all
NCT05579366
2026-05-26
RAINFOL-01
Genmab
Phase 1/2
Recruiting
884 enrolled